2015 AACR Annual Meeting

gynecologic cancers

Groups Join Together to Form Ovarian Cancer Research Team

Stand Up To Cancer , Ovarian Cancer Research Fund, Ovarian Cancer National Alliance, and National Ovarian Cancer Coalition, along with the American Association for Cancer Research (AACR), announced th...

skin cancer

Combination Immunotherapy Better Than Monotherapy in Advanced Melanoma

As clinical research struggles to keep up with the pace of new immunotherapies, one of the burning questions is how best to combine the new drugs. A new study found that the combination of nivolumab (...

skin cancer

Practice-Changing Study: Pembrolizumab Outperforms Ipilimumab in Advanced Melanoma

Pembrolizumab (Keytruda) proved superior to ipilimumab (Yervoy) for the treatment of unresectable advanced melanoma in the global phase III KEYNOTE-006 trial. Pembrolizumab significantly improved over...

Prostate Cancer

Prostate Tumors With Genetic Abnormalities Respond to Olaparib

Olaparib (Lynparza) achieved encouraging response rates in men with metastatic prostate cancer, particularly those with mutations in genes involved in DNA repair (BRCA2 and ATM, most commonly).1 If va...

Richard Pazdur, MD, Receives AACR Public Service Award

Richard Pazdur, MD, was awarded the American Association of Cancer Research’s (AACR) Distinguished Public Service Award at the 2015 AACR Annual Meeting. The Association chose Dr. Pazdur for this award...

Symptom Management

Adoptive T-Cell Therapy Successfully Treats Devastating Complication of Stem Cell Transplantation

A new “off-the-shelf” treatment promises to induce remission in rituximab (Rituxan)-refractory Epstein-Barr virus (EBV)-associated lympho­proliferative disorder, a potentially fatal complication of he...

Pancreatic Cancer
Issues in Oncology

Many Miles to Go: Targeted Treatment Based on Whole-Genome Sequencing

The ability to do genomic analysis of patients’ tumors holds great promise for revolutionizing cancer treatment, and genomics has already made some great strides. However, the Individualized Molecular...

Lung Cancer

Pembrolizumab Safe and Effective in Patients With NSCLC, Especially in Those With Tumors Showing High Levels of PD-L1 Expression

Add lung cancer to the growing list of cancers that may derive benefit from immunotherapy. The KEYNOTE-001 trial found that pembrolizumab (Keytruda) achieved durable responses in a proportion of patie...

Breast Cancer

Anti–PD-L1 Agent Shows Activity in Early Study of Triple-Negative Breast Cancer

An investigational immunotherapy called MPDL3280A showed encouraging and durable clinical activity in heavily pretreated patients with metastatic triple-negative breast cancer, in an early study prese...

Advertisement

Advertisement



Advertisement